Elevate and De-Risk Your Drug Portfolio Strategy With AI

Join our panelists as they discuss using AI and insights tools to enhance PTRS, prioritize assets, and guide strategic development decisions.

Register Free: https://www.pharmexec.com/pe_w/strategy-with-ai

Event Overview:

Risks, critical decisions, and subjectivity surface at various points in drug development. So, how do data-driven insights and AI reduce risk and improve quantitative rigor? This conversation will cover perspectives and approaches to elevate portfolio strategy capabilities and de-risk drug development. You'll hear industry leaders who have used decision sciences and AI to empower operational and business goals. The panelists will share how they have used AI and insights tools to validate and calibrate the probability of technical and regulatory success (PTRS), support asset prioritization, and inform pipeline performance and strategic decisions about asset development. In addition, learn how real-time updates on your portfolio and competitors can level up your acquisition and licensing efforts.

Key Learning Objectives

• Learn how to increase R&D ROI, accelerate time-to-market, and inform smarter investments using AI-driven PTRS assessments.
• Identify indications that present the best chances for certain types of assets to succeed using the latest clinical developments.
• Target methods to help reduce inherent biases by incorporating quantitative rigor into decision-making.

Who Should Attend

Professionals who are in the following roles:

• Portfolio strategy/management
• Program management
• Decision sciences
• Competitive intelligence
• External innovation
• New product planning
• Clinical development
• Strategic insights
• Performance analytics
• Quantitative advanced analytics

Speakers:

John McGrath
Course Director MSc, Project Management
Technological University Dublin

John McGrath is a tenured professor who is the course director for the Master of Science in project management program at Technological University Dublin in Ireland. He has over 25 years of experience teaching, coaching, and consulting on project management issues. He started his career with Pfizer and has assisted over 150 global companies, government agencies, and state enterprises, including Engineers Ireland, the United Nations, the Paralympics in both London, England, and Rio de Janeiro, Brazil, and the World Bank.

He has a particular interest in developing PPM competencies within organizations and gaining true visibility of the project/program pipeline, a process that he commonly refers to as searching for a Single Version of the Truth. Three decades of experience have taught McGrath that excellence in project execution rarely happens without first achieving excellence in decision-making.

Panos Karelis, M.Eng., M.Sc.
Director of Customer Experience and Insights
Intelligencia

Panos Karelis, M.S., M.Sc., M.Eng., is director of customer experience and insights with Intelligencia AI, where he focuses on unlocking value for the company’s partners through best-in-class thought partnerships and bespoke analytics that harness the company’s proprietary data. He brings over a decade of experience in the life sciences industry, helping North American and European pharmaceutical and biotech companies develop products, therapeutic areas, and portfolio strategies.

Before joining Intelligencia AI, Karelis was a principal with Strategic Decisions Group, a management consulting firm focusing on decision-making. He began his career in the energy sector. He is an engineer by training with a background in economics, finance, and decision analysis.

Karelis holds a master of science degree in management science and engineering from Stanford University; a master of science in energy production and management; and a master of engineering in electrical engineering and computer science, both from the National Technical University of Athens in Greece.

Ivan Kugener, MD
VP, Head of Global Portfolio Management, Valuation and Analytics
EMD Serono

In his current role as vice president and head of global portfolio management, valuation, and analytics, and for the past 11 years, Ivan Kugener, MD, has supported EMD Serono's pharmaceutical pipeline decision-making process. Dr. Kugener began his career in the French Navy, reaching the rank of Captain at age 25. He then spent over 7 years at Abbott and nearly 5 years at Medtronic. For 7 years, he worked at a private Swiss bank, Lombard Odier Darier Hentsch, managing a team of 5 with more than $2 billion invested in health care, private, and public equities. In 2008, he transitioned back to the pharmaceutical industry, where he joined EMD Serono, as head of US strategy. At ArthroCare, he led preclinical and clinical development and medical affairs. Educated as a medical doctor and board-certified, Dr. Kugener supplemented his education with master’s degrees in business administration and mathematics.

Joshua Hattem, MBA
Principal, Portfolio Strategy Practice Lead
ZS

Joshua Hattem, MBA, is part of the pipeline and launch strategy practice at ZS in Philadelphia, Pennsylvania, where he is principal and leads the team within the practice and the company’s portfolio strategy service line.

Hattem focuses on helping pharmaceutical companies develop strategies for product development and commercialization. His passion lies at the intersection of science and business, working with clients to develop cross-functional strategies for their products, portfolios, and capabilities that bridge commercial, medical, and clinical. Hattem specializes in challenges such as market mapping and market shaping, portfolio prioritization, market segmentation, value proposition development, and evidence-generation strategy.

Register Free: https://www.pharmexec.com/pe_w/strategy-with-ai